Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma
Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma
复制标题
CD133肿瘤干细胞在喉癌中的化疗耐药性
DOI：
10.3760/cma.j.issn.0366-6999.2011.07.020
复制
发表时间：
2011-04-05
影响因子：
6.1
通讯作者：
Jin Chun-shun
中科院分区：
文献类型：
--
作者：
Yang Jing-pu;Liu Yan;Jin Chun-shun
背景越来越多的证据表明，肿瘤在组织学上是异质性的，并由一小群称为癌症干细胞的肿瘤细胞维持。CD 133已被确定为喉癌中癌干细胞的候选标志物。本研究旨在分析CD 133（+）肿瘤干细胞对化疗药物的耐药性。应用流式细胞仪检测CD 133（+）细胞亚群，并进行集落形成实验、细胞侵袭实验、化疗耐药实验和ABCG 2基因表达的检测。结果Hep-2细胞中CD 133（+）细胞占1%~ 2%。化疗使CD 133（+）比例增加。CD 133（+）肿瘤干细胞具有更高的克隆形成和侵袭潜力，并且对化疗更具抵抗力。结论CD 133（+）肿瘤干细胞对化疗具有较强的抵抗力。ABCG 2的表达可能是部分原因。靶向这一小部分CD 133（+）癌症干细胞可能是开发更有效治疗喉癌的策略。中华医学杂志2011;124（7）：1055-1060
Background Mounting evidence suggests that tumors are histologically heterogeneous and are maintained by a small population of tumor cells termed cancer stem cells. CD133 has been identified as a candidate marker of cancer stem cells in laryngeal carcinoma. This study aimed to analyze the chemoresistance of CD133(+) cancer stem cells.Methods The response of Hep-2 cells to different chemotherapeutic agents was investigated and the expression of CD133 was studied. Fluorescence-activated cell sorting analysis was used to identify CD133, and the CD133(+) subset of cells was separated and analyzed in colony formation assays, cell invasion assays, chemotherapy resistance studies, and analyzed for the expression of the drug resistance gene ABCG2.Results About 1%-2% of Hep-2 cells were CD133(+) cells, and the CD133(+) proportion was enriched by chemotherapy. CD133(+) cancer stem cells exhibited higher potential for clonogenicity and invasion, and were more resistant to chemotherapy. This resistance was correlated with higher expression of ABCG2.Conclusions This study suggested that CD133(+) cancer stem cells are more resistant to chemotherapy. The expression of ABCG2 could be partially responsible for this. Targeting this small population of CD133(+) cancer stem cells could be a strategy to develop more effective treatments for laryngeal carcinoma. Chin Med J 2011;124(7):1055-1060